Here are the 10-K annual reports from Provectus Biopharms (PVCT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVCT filings page.
Provectus Biopharmaceuticals, Inc. files its 2025 annual report outlining a broad rose bengal sodium (RBS)–based immunotherapy platform, spanning oncology, dermatology, ophthalmology and multiple early non-clinical programs. The company highlights an extensive U.S. and international patent estate supporting its pharmaceutical-grade RBS and PV‑10/PH‑10 candidates.
The report warns of substantial doubt about the company’s ability to continue as a going concern, citing an accumulated net loss of approximately $263 million since inception, a cash balance of $251,291 and a working capital deficit of $6,329,503 as of December 31, 2025. Management states that additional capital will be required in 2026 and beyond to advance clinical trials and operations.
As of June 30, 2025, the aggregate market value of common equity held by non‑affiliates was $30,585,685, based on a price of $0.075 per share. There were 420,279,879 shares of common stock outstanding as of March 23, 2026. The company also discloses cybersecurity, environmental and human‑capital practices, including a six‑person full‑time workforce and use of cloud‑based, third‑party monitored IT systems.